
    
      PRIMARY OBJECTIVES:

      I. Determine the efficacy and safety of FR901228 (depsipeptide) in patients with metastatic
      breast cancer.

      SECONDARY OBJECTIVES:

      I. Determine the clinical activity of this drug, in terms of progression-free survival, in
      these patients.

      OUTLINE: This is a multicenter study.

      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 2.4-12.3
      months.
    
  